| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
IDH1
|
|---|---|
| ln Vitro |
Safusidenib (DS-1001b) reduces 2-HG levels and hinders the growth of chondrosarcoma cell lines with an IDH1 mutation[1]. While safusidenib has no influence on the proliferation of IDH wild-type cell lines OUMS27 and NDCS-1, it affects the proliferation of IDH1 mutant chondrosarcoma cell lines in a dose-dependent manner (GI50 values for JJ012, L835, OUMS27, and NDCS-1 cells are 81?Day 14 of nM, 77?nM (6 weeks), greater than 10?Day 10 at μM and above 10?μM (day 10) in that order[1]. At the protein level, safusidenib (1 and 10?μM; for 6 weeks) significantly upregulates SOX9, a crucial regulator of chondrocyte differentiation[1]. The protein level of CDKN1C is markedly upregulated by safusidenib (1 μM)[1]. In experiments involving a 2-hour preincubation step, safusidenib (DS-1001b) demonstrates action against IDH1 or IDH2 enzymes with IC50s of 8.4, 11, and 180 nM for IDH1R132H, IDH1R132C, and IDH1WT[2].
|
| ln Vivo |
In JJ012 xenografts, sofusidenib (DS-1001b) exhibits antineoplastic action. In xenograft mice, constant feeding of Safusidenib (combined with sterile pellet meal and administered continuously for 6 weeks) inhibits the formation of tumors[1].
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: The IDH1 mutant cell lines JJ012 and L835 cells Tested Tested Concentrations: 0.1, 1, and 10 μM Incubation Duration: 0, 3, 6, 9, 12, and 15 days Experimental Results: Impaired proliferation in both cell lines in a dose-dependent manner. Western Blot Analysis[1] Cell Types: L835 cells Tested Tested Concentrations: 0, 1, and 10 μM Incubation Duration: 6 weeks Experimental Results: Markedly upregulated SOX9 at the protein level. |
| Animal Protocol |
Animal/Disease Models: NOD-SCID bearing JJ012 xenograft[3]
Doses: Mixed with sterilized pellet food (CRF-1; Oriental Yeast) and fed ad libitum for 6 weeks. Route of Administration: Fed continuously starting at 3 weeks Experimental Results: Continuous administration Dramatically impaired tumor growth in JJ012 xenograft mice. |
| References |
|
| Additional Infomation |
Safusidenib is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble) mutant forms, including substitution mutations at the arginine in position 132, IDH1(R132) (IDH1-R132), with potential antineoplastic activity. Upon oral administration, safusidenib specifically binds to and inhibits certain mutant forms of IDH1, thereby inhibiting the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH1 mutations. IDH1(R132) mutations are highly expressed in certain malignancies, including gliomas; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG. Safusidenib minimally targets and affects wild-type IDH1, which is expressed in normal, healthy cells.
|
| Molecular Formula |
C25H18CL3FN2O4
|
|---|---|
| Molecular Weight |
535.778827190399
|
| Exact Mass |
534.031
|
| CAS # |
1898206-17-1
|
| Related CAS # |
DS-1001b;1898207-64-1
|
| PubChem CID |
130306983
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
6.6
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
35
|
| Complexity |
834
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CN(C2=CC=CC(=C12)/C=C/C(=O)O)C(=O)C3=C(ON=C3C4=C(C=C(C=C4Cl)Cl)Cl)C(C)(C)F
|
| InChi Key |
BOOMBLZEOHXPPX-BQYQJAHWSA-N
|
| InChi Code |
InChI=1S/C25H18Cl3FN2O4/c1-12-11-31(17-6-4-5-13(19(12)17)7-8-18(32)33)24(34)21-22(30-35-23(21)25(2,3)29)20-15(27)9-14(26)10-16(20)28/h4-11H,1-3H3,(H,32,33)/b8-7+
|
| Chemical Name |
(E)-3-[1-[5-(2-fluoropropan-2-yl)-3-(2,4,6-trichlorophenyl)-1,2-oxazole-4-carbonyl]-3-methylindol-4-yl]prop-2-enoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8664 mL | 9.3322 mL | 18.6644 mL | |
| 5 mM | 0.3733 mL | 1.8664 mL | 3.7329 mL | |
| 10 mM | 0.1866 mL | 0.9332 mL | 1.8664 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
